Oral Answers to Questions

Caroline Nokes Excerpts

Wednesday 8th July 2015 Commons Chamber

[The Prime Minister]

The hon. Gentleman is absolutely right, and that is why I met the Bosnian President this week to discuss some of those issues, as well as to talk about commemorating and remembering Srebrenica. What matters is making sure that the institutions in Bosnia work better, and the politicians work better together in understanding their past and their shared future. It is very important that we keep the door of access to the European Union open, but for that to happen the institutions need improving and issues need to be dealt with properly—corruption and problems need to be addressed. But there is no doubt in my mind that the pathway to membership of the European Union has helped in Bosnia, as it can help in the rest of the western Balkans, and it is vital that we keep that door open.

[Caroline Nokes (Romsey and Southampton North) (Con)]

Q15. Seven-year-old Jagger Curtis from Romsey suffers from Duchenne muscular dystrophy. Every day that he waits for first NHS England and now the National Institute for Health and Care Excellence to make a decision about Translarna is a day that threatens his mobility. Last week’s decision to delay, potentially for up to five months, was a bitter blow. What action can my right hon. Friend take to make sure that NICE makes that decision with the utmost speed?

[The Prime Minister]

My hon. Friend rightly raises this issue, and I say to her that these are incredibly difficult decisions and we know how hard they are for patients and their families. I think it is right that it is expert clinicians at NHS England and not politicians who make these funding decisions, based on the available evidence. As she knows, NICE has not yet made a final decision on these drugs, so patients and their families, and other experts, can feed into its evidence-gathering and consultation process. She asks what we can do, and I think there are two things. First, when we have these drugs that cost over £400,000 per patient per year, it is right to ask some pretty challenging questions of the companies concerned and we should do so. Secondly, we must keep investing in our rare disease research and in genomics, and making sure that the NHS takes up these treatments rapidly. That is the sort of health service we want to build.